Authored by Karl Simpson
Prosensa HoldingsN.V, the drug development company focused on advancing therapies for duchenne muscular dystrophy announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and the addition of Dr. Annalisa Jenkins to its Supervisory Board.
With more than two decades of experience at Genzyme and GSK and his recent leadership of Dutch to-BBB as CEO, Mr. van Weperen brings significant business operational and commercial expertise to Prosensa.
Dr. Annalisa Jenkins joins Prosensa’s Supervisory Board with more than 25 years of experience in the healthcare sector. In her most recent role as Head of Global Research and Development and Executive Vice President at Merck Serono, which she has held since October 2013, she was responsible for building global development, research and medical capabilities, spanning research, development, global regulatory and clinical development in addition to medical affairs and patient access.
“We are delighted to welcome Annalisa to Prosensa’s Supervisory Board. Her extensive experience in research and clinical development and medical affairs for Merck Serono and Bristol Myers Squibb, which are amongst the top pharma companies in the world, will bring valuable insights to us as we take the company to the next level,” said David Mott, Chairman of the Supervisory Board at Prosensa.
The appointment of Dr. Annalisa Jenkins will be subject to shareholders’ approval at the next shareholders’ meeting, scheduled for August 20, 2014.